Meeder Asset Management Inc. raised its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 6.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 104,774 shares of the company’s stock after buying an additional 6,262 shares during the quarter. AbbVie comprises about 1.4% of Meeder Asset Management Inc.’s investment portfolio, making the stock its 19th biggest holding. Meeder Asset Management Inc.’s holdings in AbbVie were worth $27,408,000 as of its most recent filing with the Securities and Exchange Commission.
Other large investors have also added to or reduced their stakes in the company. Capital Advisors Inc. OK boosted its holdings in shares of AbbVie by 11.2% in the 2nd quarter. Capital Advisors Inc. OK now owns 447,129 shares of the company’s stock valued at $112,516,000 after purchasing an additional 45,132 shares in the last quarter. Danica Pension Livsforsikringsaktieselskab acquired a new position in shares of AbbVie during the 2nd quarter worth $23,557,000. State Street Corp raised its holdings in shares of AbbVie by 1.7% during the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after buying an additional 1,379,232 shares in the last quarter. Wedge Capital Management L L P NC lifted its position in shares of AbbVie by 7.5% during the 2nd quarter. Wedge Capital Management L L P NC now owns 134,579 shares of the company’s stock worth $33,865,000 after buying an additional 9,380 shares during the last quarter. Finally, Apollon Wealth Management LLC lifted its position in shares of AbbVie by 18.6% during the 3rd quarter. Apollon Wealth Management LLC now owns 145,103 shares of the company’s stock worth $37,957,000 after buying an additional 22,722 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.
Analyst Upgrades and Downgrades
A number of research analysts have issued reports on the company. HSBC lifted their target price on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Scotiabank increased their target price on shares of AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Guggenheim raised their price target on shares of AbbVie from $288.00 to $322.00 and gave the company a “buy” rating in a research note on Monday, November 2nd. Argus lifted their price target on shares of AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. Finally, Piper Sandler set a $349.00 price target on shares of AbbVie and gave the company an “overweight” rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $299.62.
Check Out Our Latest Report on AbbVie
Insider Buying and Selling
In related news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $293.60, for a total transaction of $11,925,738.40. Following the sale, the executive vice president directly owned 83,171 shares in the company, valued at $24,419,005.60. This trade represents a 32.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.06% of the stock is currently owned by corporate insiders.
AbbVie Stock Down 2.4%
Shares of ABBV opened at $285.92 on Thursday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $302.93. The business has a 50-day simple moving average of $277.84 and a two-hundred day simple moving average of $241.96. The stock has a market cap of $505.39 billion, a PE ratio of 49.21, a PEG ratio of 1.33 and a beta of 0.20.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $3.82 EPS for the quarter, beating the consensus estimate of $3.73 by $0.09. The firm had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a negative return on equity of 450.55% and a net margin of 15.67%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the company earned $1.86 earnings per share. On average, equities research analysts expect that AbbVie Inc. will post 13.98 EPS for the current year.
AbbVie Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be given a dividend of $1.82 per share. The ex-dividend date is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. This is a boost from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio is 119.10%.
AbbVie Company Profile
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Articles
- Five stocks we like better than AbbVie
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
